Myriad360 Acquires Advizex Technologies to Form $900M Global AI and Enterprise Infrastructure Platform 
What Security Teams Still Get Wrong About CVEs at Scale 
Shoucheng Expands Robotics Retail Footprint Ahead of Lunar New Year, Opens Three Beijing Stores Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study
Preliminary data from the Phase 1/2 trial of PORT-2 demonstrates favorable safety and tolerability as…
Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB),…
Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference
OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizures…
AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual Meeting
Exploratory long-term OS analyses of TIVO-3 continue to trend in favor of tivozanib, patients with…
Apexigen Announces Nature Medicine Publication and ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and/or Nivolumab in Combination with Chemotherapy
– Data from the Parker Institute for Cancer Immunotherapy and Cancer Research Institute multi-center Phase…
GBT’s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease
Inclacumab is a novel P-selectin inhibitor currently in Phase 3 clinical trials to reduce vaso-occlusive…
Enlivex Receives Israeli Ministry of Health Authorization for the Initiation of a Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers
Trial will be the first clinical study of Allocetra™ in patients with cancer, following encouraging…
Ayala Pharmaceuticals Announces Data on AL101 in Adenoid Cystic Carcinoma (ACC) at 2022 ASCO Annual Meeting
— Presentation at ASCO features updated results from Phase 2 ACCURACY study — — AL101…
AGTC to Present Three-Month Interim Results from the SKYLINE Clinical Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa at the 45th Macula Society Annual Meeting
GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC),…
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON and LONDON, June 06, 2022 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a…
Molecular Templates’ Presentations at the 2022 ASCO Annual Meeting Demonstrate Advancement in PD-L1 and HER2 Programs
Presentations on the MT-6402 (PD-L1) and MT-5111(HER2) Phase I dose escalation programs demonstrate unique biology,…
Aligos Therapeutics to Participate in Metropolitan AntiViral Drug Accelerator, Recipient of NIH and NIAID Grant to Develop Therapeutics Against Coronaviruses and Pathogens of Pandemic Potential
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS),…
Black Diamond Therapeutics to Present at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc….
ORYZON to Give Updates on Corporate Progress in June
Jefferies Healthcare Conference European Hematology Association Congress, EHA-2022 BIO International Convention LSX World Congress MADRID,…
Reflect Scientific Inc Receives Patent for Green Cooling Technology
OREM, Utah, June 06, 2022 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (Symbol: RSCF), a provider…
MedMira Receives Patent for its Unique Quantitative Diagnostic System
HALIFAX, Nova Scotia, June 06, 2022 (GLOBE NEWSWIRE) — Today, MedMira Inc. (MedMira) (TSXV: MIR)…
Praxis Precision Medicines Reports Negative Results from PRAX-114 Phase 2/3 Monotherapy Aria Study in Patients with Major Depressive Disorder
Aria Study did not achieve statistical significance on the primary endpoint Strategic realignment to focus…
Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus
Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA…
Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022
PHILADELPHIA, June 06, 2022 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company…
BridgeBio Pharma to Participate in June Investor Events
PALO ALTO, Calif., June 06, 2022 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”…